Dr. Reddy's Laboratories Limited (RDY)
After hours:
| Previous Close | 74.88 |
| Open | 73.23 |
| Bid | 70.00 x 800 |
| Ask | 72.92 x 1100 |
| Day's Range | 71.12 - 74.47 |
| 52 Week Range | 53.12 - 77.72 |
| Volume | |
| Avg. Volume | 186,096 |
| Market Cap | 11.989B |
| Beta (5Y Monthly) | 0.34 |
| PE Ratio (TTM) | 18.97 |
| EPS (TTM) | 3.76 |
| Earnings Date | May 07, 2024 |
| Forward Dividend & Yield | 0.49 (0.65%) |
| Ex-Dividend Date | Jul 07, 2023 |
| 1y Target Est | 79.88 |
Business WireDr. Reddy’s Q4 & Full Year FY24 Financial Results
HYDERABAD, India, May 07, 2024--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024.
Business WireDr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
HYDERABAD, India, May 03, 2024--Dr. Reddy's Laboratories announces the launch of Doxycycline Capsules, 40 mg* in the U.S. market.
GlobeNewswirePharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
